TABLE 2.

Doubling times of plasma HIV RNA during STIs and first- and second-phase decay half-lifes after resumption of treatment

Patient no.	VL (copies/ml)		Doubling time (days) during STI:					First-phase decay half-life (days) after STI:				Second-phase decay half-life (days) after STI:
	Pretreatment	Plateau	1	2	3	4	5	1	2	3	4	1	2	3	4
1	561,831	76,805	1.18	1.24	1.15	2.10	1.49	1.48	1.42	1.52	NAa	15.53	18.85	27.31	15.11
2	80,600	21,393	NA	NA	NA	NA	1.33	NA	NA	NA	NA	NA	NA	NA	NA
3	34,752	115,546	0.78	1.31	1.26	1.33	1.33	3.06	1.98	2.26	1.77	16.32	16.35	10.57	15.19
4	122,729	19,344	1.04	1.21	1.25	1.29	1.35	2.26	1.23	2.21	1.93	12.06	8.80	10.05	11.14
5	32,140	6,459	10.26	4.89	1.52	1.13	3.56	2.10	1.42	1.49	1.78	NA	NA	18.19	14.01
6	467,598	31,500	1.06	0.85	1.28	1.38	1.25	1.61	1.18	1.59	1.26	13.12	10.92	14.83	10.65
7	16,927	3,140	0.95	1.01	1.99	1.21	1.48	1.16	1.94	NA	1.07	1,664.09	6.05	NA	14.08
8	150,390	40,176	3.67	1.74	8.00	3.31	1.35	5.63	2.05	14.27	1.88	32.94	−95.31	11.20	NA
9	164,772	65,941	1.38	1.46	3.18	2.36	1.78	1.94	1.02	17.69	NA	9.70	18.88	12.40	11.76
10	11,298	4,623	1.97	7.86	3.67	1.26	3.58	2.00	2.13	1.38	1.24	−48.28	NA	NA	NA
11	25,417	106,928	2.01	2.15	2.73	2.46	3.16	2.22	8.48	1.98	3.54	−72.05	19.87	−20.33	−57.25
12	9,404	20,236	1.00	1.25	0.99	2.86	7.65	1.17	1.37	NA	1.88	14.87	13.17	21.65	21.15
13	537	105	NA	NA	NA	NA	1.86	NA	NA	NA	NA	NA	NA	NA	NA
Mean			2.30	2.27	2.46	1.88	2.40	2.24	2.20	4.93	1.82	165.83	1.96	11.76	6.20

^aNA, not available (either no rebound was observed during the 2-week STI or not enough data points were available to calculate first- and second-phase half-lives).